The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy

Thrombosis Research

Volumn 112, Issue 1-2, 2003, Pages 13-18

  Rodger, Marc A ^a,b,c   Gagné Rodger, Christine ^c   Howley, Heather E ^b   Carrier, Marc ^a,c   Coyle, Doug ^a,b   Wells, Philip S ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cost shifting; DVT therapy; Outpatient treatment; Patient costs

Indexed keywords

HEPARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DEEP VEIN THROMBOSIS; FAMILY; FEMALE; HEALTH CARE COST; HEPARINIZATION; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; MALE; OUTPATIENT CARE; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE;

EID: 0842346039     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.09.027     Document Type: Article

References (29)

1. Anderson F.A.J., Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B.et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. 151(5):1991;933-938.
2. Ginsberg J.S. Management of venous thromboembolism [see comments]. N. Engl. J. Med. 335(24):1996;1816-1828.
3. Leizorovicz A., Simonneau G., Decousus H., Boissel J.P. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. 309(6950):1994;299-304.
4. Lensing A.W., Prins M.H., Davidson B.L., Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch. Intern. Med. 155(6):1995;601-607.
5. Siragusa S., Cosmi B., Piovella F., Hirsh J., Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. 100(3):1996;269-277.
6. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 130(10):1999;800-809.
7. Levine M., Gent M., Hirsh J., Leclerc J., Anderson D., Weitz J.et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis [see comments]. N. Engl. J. Med. 334(11):1996;677-681.
8. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., van der Meer J.et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N. Engl. J. Med. 334(11):1996;682-687.
9. Lindmarker P., Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. J. Intern. Med. 240(6):1996;395-401.
10. Tillman D.J., Charland S.L., Witt D.M. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch. Intern. Med. 160(19):2000;2926-2932.
11. Wells P.S., Kovacs M.J., Bormanis J., Forgie M.A., Goudie D., Morrow B. et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin - a comparison of patient self-injection with homecare injection. Arch. Intern. Med. 158(16):1998;1809-1812.
12. Harrison L., McGinnis J., Crowther M., Ginsberg J., Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch. Intern. Med. 158(18):1998;2001-2003.
13. Rodger M., Bredeson C., Wells P.S., Beck J., Kearns B., Huebsch L.B. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis [see comments]. CMAJ. 159(8):1998;931-938.
14. Ting S.B., Ziegenbein R.W., Gan T.E., Catalano J.V., Monagle P., Silvers J.et al. Dalteparin for deep venous thrombosis: a hospital-in-the-home program. Med. J. Aust. 168(6):1998;272-276.
15. Groce J.B. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Pharmacotherapy. 18(6 Pt 3):1998;175S-180S.
16. Estrada C.A., Mansfield C.J., Heudebert G.R. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. J. Gen. Intern. Med. 15(2):2000 (Feb.);108-150. [AD/15 (2) 2 108-115].
17. van den Belt A.G., Bossuyt P.M., Prins M.H., Gallus A.S., Buller H.R. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. TASMAN Study Group. Thromb. Haemost. 79(2):1998;259-263.
18. O'Brien B., Levine M., Willan A., Goeree R., Haley S., Blackhouse G.et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch. Intern. Med. 159(19):1999;2298-2304.
19. Mitchell J.B., Harrow B. Costs and outcomes of inpatient versus outpatient hernia repair. Health Policy. 28(2):1994;143-152.
20. Lacerda-Filho A., Cunha-Melo J.R. Outpatient haemorrhoidectomy under local anaesthesia. Eur. J. Surg. 163(12):1997;935-940.
21. Bentkover S.H., Kozlicak B.A., Girouard S. Outpatient parotidectomy at the Fallon Clinic. The first 2 years [see comments]. Arch. Otolaryngol. Head Neck Surg. 122(10):1996;1049-1053.
22. Lee J.C., Bengtson J.R., Lipscomb J., Bashore T.M., Mark D.B., Califf R.M.et al. Feasibility and cost-saving potential of outpatient cardiac catheterization. J. Am. Coll. Cardiol. 15(2):1990;378-384.
23. Fleisher L.A., Yee K., Lillemoe K.D., Talamini M.A., Yeo C.J., Heath R. et al. Is outpatient laparoscopic cholecystectomy safe and cost-effective? A model to study transition of care. Anesthesiology. 90(6):1999;1746-1755.
24. Chamberlain T.M., Lehman M.E., Groh M.J., Munroe W.P., Reinders T.P. Cost analysis of a home intravenous antibiotic program. Am. J. Hosp. Pharm. 45(11):1988;2341-2345.
25. Del Prete S.A., Ryan S.P., Jacobson J.S., Erichson R.B., Weinstein P.L., Grann V.R. Safety and costs of treating neutropenic fever in an outpatient setting. Conn. Med. 63(12):1999;713-717.
26. Rizzo J.D., Vogelsang G.B., Krumm S., Frink B., Mock V., Bass E.B. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J. Clin. Oncol. 17(9):1999;2811-2818.
27. Meisenberg B.R., Ferran K., Hollenbach K., Brehm T., Jollon J., Piro L.D. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. 21(9):1998;927-932.
28. Miller W.J. Disparities in prescription drug insurance coverage. Health Rep. 10(4):2001;11-31. [Statistics Canada, Catalogue 82-003-XIE].
29. Chaplin R., Earl L. Household spending on health care. Health Rep. 12(1):2000;57-65. [Statistics Canada, Catalogue 82-003-XIE].